The role of MMP-14 in the development and progression of Prostate Cancer: A Scoping Review Protocol

Calum Turpie; Paul J Dunn; Wyatt Melkonian; Lauren Canning; Catherine McDermott; Joan Rohl

doi:10.17605/OSF.IO/YCU5E

The role of MMP-14 in the development and progression of Prostate Cancer: A Scoping Review Protocol

Calum Turpie, Paul J Dunn, Wyatt Melkonian, Lauren Canning, Catherine McDermott, Joan Rohl

Research output: Other contribution › Discipline Preprint Repository › Research

Abstract

Prostate cancer (PCa) is the second most common malignancy in men globally, with approximately 1.4 million cases being reported in 2020. Despite advancements in treatment, PCa remains a leading cause of cancer death, which has been increasingly linked to metastatic development. Matrix Metalloproteinase-14 (MMP-14) is an enzyme involved in the breakdown of the extracellular matrix, promoting cancer cell invasion and angiogenesis. It is associated with poor prognostic outcomes in various cancers, though its specific role in prostate cancer remains debated. This review aims to map and summarize existing literature on MMP-14's involvement in PCa pathogenesis, including its utilisation as a marker for diagnosis, therapy, and/or prognosis of prostate cancer. In this protocol we describe our eligibility (inclusion/exclusion) criteria, search strategy, and our planned methods of screening, extracting and synthesising data.

Original language	English
Publisher	Open Science Framework Registries
DOIs	https://doi.org/10.17605/OSF.IO/YCU5E
Publication status	Submitted - 6 Sept 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.17605/OSF.IO/YCU5ELicence: CC BY

Cite this

@misc{192f5cda240c49d4ba9aa59c357619f3,

title = "The role of MMP-14 in the development and progression of Prostate Cancer: A Scoping Review Protocol",

abstract = "Prostate cancer (PCa) is the second most common malignancy in men globally, with approximately 1.4 million cases being reported in 2020. Despite advancements in treatment, PCa remains a leading cause of cancer death, which has been increasingly linked to metastatic development. Matrix Metalloproteinase-14 (MMP-14) is an enzyme involved in the breakdown of the extracellular matrix, promoting cancer cell invasion and angiogenesis. It is associated with poor prognostic outcomes in various cancers, though its specific role in prostate cancer remains debated. This review aims to map and summarize existing literature on MMP-14's involvement in PCa pathogenesis, including its utilisation as a marker for diagnosis, therapy, and/or prognosis of prostate cancer. In this protocol we describe our eligibility (inclusion/exclusion) criteria, search strategy, and our planned methods of screening, extracting and synthesising data.",

author = "Calum Turpie and Dunn, {Paul J} and Wyatt Melkonian and Lauren Canning and Catherine McDermott and Joan Rohl",

year = "2024",

month = sep,

day = "6",

doi = "10.17605/OSF.IO/YCU5E",

language = "English",

publisher = "Open Science Framework Registries",

type = "Other",

}

TY - GEN

T1 - The role of MMP-14 in the development and progression of Prostate Cancer: A Scoping Review Protocol

AU - Turpie, Calum

AU - Dunn, Paul J

AU - Melkonian, Wyatt

AU - Canning, Lauren

AU - McDermott, Catherine

AU - Rohl, Joan

PY - 2024/9/6

Y1 - 2024/9/6

N2 - Prostate cancer (PCa) is the second most common malignancy in men globally, with approximately 1.4 million cases being reported in 2020. Despite advancements in treatment, PCa remains a leading cause of cancer death, which has been increasingly linked to metastatic development. Matrix Metalloproteinase-14 (MMP-14) is an enzyme involved in the breakdown of the extracellular matrix, promoting cancer cell invasion and angiogenesis. It is associated with poor prognostic outcomes in various cancers, though its specific role in prostate cancer remains debated. This review aims to map and summarize existing literature on MMP-14's involvement in PCa pathogenesis, including its utilisation as a marker for diagnosis, therapy, and/or prognosis of prostate cancer. In this protocol we describe our eligibility (inclusion/exclusion) criteria, search strategy, and our planned methods of screening, extracting and synthesising data.

AB - Prostate cancer (PCa) is the second most common malignancy in men globally, with approximately 1.4 million cases being reported in 2020. Despite advancements in treatment, PCa remains a leading cause of cancer death, which has been increasingly linked to metastatic development. Matrix Metalloproteinase-14 (MMP-14) is an enzyme involved in the breakdown of the extracellular matrix, promoting cancer cell invasion and angiogenesis. It is associated with poor prognostic outcomes in various cancers, though its specific role in prostate cancer remains debated. This review aims to map and summarize existing literature on MMP-14's involvement in PCa pathogenesis, including its utilisation as a marker for diagnosis, therapy, and/or prognosis of prostate cancer. In this protocol we describe our eligibility (inclusion/exclusion) criteria, search strategy, and our planned methods of screening, extracting and synthesising data.

U2 - 10.17605/OSF.IO/YCU5E

DO - 10.17605/OSF.IO/YCU5E

M3 - Discipline Preprint Repository

PB - Open Science Framework Registries

ER -